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Abstract
Background: In the absence of clinical trial data, large post-marketing observational studies are essential to evaluate the
safety and effectiveness of medications during pregnancy. We identified a cohort of pregnancies ending in live birth within
the 2000–2007 Medicaid Analytic eXtract (MAX). Herein, we provide a blueprint to guide investigators who wish to create
similar cohorts from healthcare utilization data and we describe the limitations in detail.
Methods: Among females ages 12–55, we identified pregnancies using delivery-related codes from healthcare utilization
claims. We linked women with pregnancies to their offspring by state, Medicaid Case Number (family identifier) and
delivery/birth dates. Then we removed inaccurate linkages and duplicate records and implemented cohort eligibility criteria
(i.e., continuous and appropriate enrollment type, no private insurance, no restricted benefits) for claim information
completeness.
Results: From 13,460,273 deliveries and 22,408,810 child observations, 6,107,572 pregnancies ending in live birth were
available after linkage, cleaning, and removal of duplicate records. The percentage of linked deliveries varied greatly by
state, from 0 to 96%. The cohort size was reduced to 1,248,875 pregnancies after requiring maternal eligibility criteria
throughout pregnancy and to 1,173,280 pregnancies after further applying infant eligibility criteria. Ninety-one percent of
women were dispensed at least one medication during pregnancy.
Conclusions: Mother-infant linkage is feasible and yields a large pregnancy cohort, although the size decreases with
increasing eligibility requirements. MAX is a useful resource for studying medications in pregnancy and a spectrum of
maternal and infant outcomes within the indigent population of women and their infants enrolled in Medicaid. It may also
be used to study maternal characteristics, the impact of Medicaid policy, and healthcare utilization during pregnancy.
However, careful attention to the limitations of these data is necessary to reduce biases.
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Introduction
In the United States (US), 50–70% of pregnant women use at
least one prescription drug during their pregnancy [1–2]. Because
pregnant women are routinely excluded from randomized
controlled trials [3], post-marketing observational studies provide
the information on the effectiveness and safety of medications in
pregnancy. Moreover, since many pregnancy outcomes of interest
are very rare (e.g., specific malformations occur in 1–30 per
10,000 live births [4]), epidemiologic studies of medications in
PLOS ONE | www.plosone.org 1 June 2013 | Volume 8 | Issue 6 | e67405pregnancy require large data sources. In this context, healthcare
utilization databases are an important resource for the study of
medications [5].
Medicaid is the joint state and federal health insurance
program in the US for low-income individuals. States provide
Medicaid claims to the Centers for Medicare and Medicaid
Services (CMS) through the Medicaid Statistical Information
System (MSIS), and Medicaid Analytic eXtract (MAX) data are
extracted from the MSIS to support research and policy analysis
[6]. MAX data are available through CMS conditional on data
use agreements and fees [7]. The data contain beneficiary
enrollment and healthcare utilization claims, including outpa-
tient pharmacy dispensing and inpatient and outpatient
diagnosis and procedure claims. Healthcare utilization data
are collected for the administration of and payment for
healthcare services [5] and, consequently, their use for research
is not straightforward.
Medicaid covers the medical expenses of over 40% of births in
the US [8]. The population of pregnant women enrolled in
Medicaid is young, racially diverse, and low-income; this type of
population is typically underrepresented in volunteer-based studies
and in studies using private health insurance data.
Statewide Medicaid, Canadian province-wide, and health
maintenance organization healthcare utilization data have been
used to identify woman-infant linked pregnancy cohorts [9–17].
One prior study utilized a small cohort of pregnant women from
MAX who were not linked to infants [18]. However, no previous
studies have identified a woman-infant linked pregnancy cohort
from nationwide Medicaid data, which allows for a larger cohort
size and permits the study of regional variation in medication and
healthcare utilization during pregnancy.
Below we describe the methods used to identify pregnancies in
MAX, link women to their live born infants, select a cohort of
woman-infant pairs, and reduce the limitations of MAX for studies
of medications in pregnancy and other healthcare factors. We also
present the characteristics of women in the cohort and the
frequency of several pregnancy outcomes.
Materials and Methods
Data Source
We obtained MAX data for all states and Washington, DC,
except Arizona, which had inaccurate personal identifiers [19];
data for US territories were not available. Data were available
from 2000–2007, except for Maine and Tennessee between
2000–2001 because of quality concerns and for Maine between
2005–2007 because only the Prescription Drug (RX) and
Personal Summary (PS) files were available [19–20]. We utilized
the PS file to obtain demographic and enrollment information,
the Inpatient (IP) file to identify hospital diagnosis and
procedure codes, the Other Therapy (OT) file to identify
diagnosis and procedure codes from outpatient hospitals, clinics,
and physicians treating beneficiaries outside a hospital or during
a hospitalization, and the RX file to identify outpatient
pharmacy dispensings [21]. We used the state-assigned MSIS
identification number (MSIS_ID) to identify unique individuals
[22] and the state-assigned Medicaid Case Number to identify
family units [9,11]. Programming was conducted with SAS
software, Version 9.2 for Windows (SAS Institute, Inc., Cary,
North Carolina, USA). This project was approved by the
Brigham and Women’s Hospital and Harvard School of Public
Health Institutional Review Boards and a data use agreement
was approved by CMS.
Identification of Deliveries and Delivery Date Ranges
Financial criteria alone do not qualify individuals for Medicaid;
rather, individuals must also belong to an appropriate eligibility
group to qualify, namely children under age 21, adults with
dependent children, pregnant women, individuals with disabilities,
and seniors [23]. We restricted the source population to females
12–55 years old who were enrolled in Medicaid for at least one
month between 2000 and 2007 according to the PS file; thus we
excluded the small proportion of individuals who were missing
eligibility information although they had Medicaid claims [20].
We also excluded individuals whose Case Number was missing,
zero or ended in 8 zeros.
To identify inpatient deliveries from the source population, we
utilized the MAX delivery code variable, which is only available in
the IP file and identifies hospitalizations with a delivery-related
International Classification of Diseases, Ninth Revision (ICD-9)
diagnosis code [24]. We also utilized delivery-related ICD-9
procedure codes from the IP file and Current Procedural Terminology,
Fourth Edition (CPT-4) codes (Table S1 in File S1) from the OT
file that had a service date during a hospitalization. The inpatient
delivery date range was the window between the maternal
admission and discharge dates associated with the delivery-related
codes.
To identify outpatient (i.e., physician, clinic, or outpatient
hospital) delivery-related claims, we utilized the delivery procedure
codes from the OT file. A large proportion of the outpatient
delivery-related procedures were for post-partum care, which
could occur several days after delivery. We defined the outpatient
delivery date range as the five days before and after the delivery-
related procedure. If the date of an outpatient delivery-related
procedure overlapped with an inpatient delivery date range for the
same woman, then the outpatient delivery-related claim was
removed.
A woman could have more than one delivery identified either
because she had more than one pregnancy during the study period
or because she had the same delivery identified more than once
with unique delivery date ranges. Instead of selecting one delivery
per woman during a certain time period [9,25], we retained all
deliveries to maximize the yield of the linkage step. Then we
removed the duplicate deliveries after linkage. As a result, the
linkage proportion that we report will be lower than algorithms
that delete duplicate deliveries prior to linkage. We identified
13,460,273 deliveries from 7,104,231 women with valid Medicaid
Case Numbers (Figure 1).
Identification of Children
We identified children with a date of birth (DOB) between
2000–2007 and a Case Number that was not missing or zero and
did not end in 8 zeros. Some MSIS_IDs are associated with more
than one DOB, e.g., correct DOB, mistyped DOB and DOB
incorrectly assigned as the first date of Medicaid eligibility. We
consolidated infants with the same Case Number and DOBs less
than three days apart after, rather than before, linkage. There
were 22,408,810 different MSIS_ID-DOB combinations available
for linkage to deliveries.
Woman-infant Linkage
Successful linkage requires the mother to be enrolled in
Medicaid on the child’s DOB, accurate recording and consistent
use of the Case Number within families, and accurate dates of
delivery and birth. Within each state, we linked women to infants
by the Case Number. Table S2 (in File S1) describes the elements
of the Case Number that were used for linkage in each state. We
were unable to identify a matching algorithm for New York
The Medicaid Analytic eXtract Pregnancy Cohort
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years. We also required that the infant’s DOB fell within the
woman’s delivery date range to link the correct siblings to each
delivery (Figure 2).
First, within each state, we linked inpatient deliveries with the
pool of child MSIS_ID-DOB combinations, and then we linked
outpatient delivery-related claims with child MSIS_ID-DOBs that
had not been linked. The delivery linkage percentage was defined
as the proportion of delivery date ranges (there could be more than
one for the same delivery) that linked to a MSIS_ID-DOB
combination (there could be more than one per infant). The child
linkage percentage was defined as the proportion of child
MSIS_ID-DOB combinations that linked to a delivery. While
generally informative, these linkage percentages should be
interpreted with caution. The same delivery could be counted in
the denominator of the delivery linkage percentage more than
Figure 1. Overview of the linkage and cohort identification process; Medicaid Analytic eXtract, 2000–2007.
doi:10.1371/journal.pone.0067405.g001
The Medicaid Analytic eXtract Pregnancy Cohort
PLOS ONE | www.plosone.org 3 June 2013 | Volume 8 | Issue 6 | e67405once if more than one delivery date range was identified, and the
same child could be counted in the denominator of the child
linkage percentage more than once if the child had more than one
MSIS_ID or DOB recorded. Likewise, linked deliveries and
children could be counted in the numerators of both percentages
more than once if the linked child had more than one MSIS_ID.
Finally, the child linkage percentages are low because not all
mothers of children from the pool were enrolled in Medicaid on
their child’s DOB, making their deliveries unavailable for linkage.
Besides matching women with their offspring, the linkage
procedure contributed to the de-duplication of infants and the
establishment of delivery date, as explained below.
Post-linkage Cleaning
To produce a cohort of unique pregnancies from the linked
deliveries, we implemented several data cleaning steps to remove
deliveries that were incorrectly linked or duplicated. To remove
incorrectly linked deliveries, we excluded all infants that were
linked to more than one woman’s MSIS_ID. Then we removed all
deliveries that were linked to infant MSIS_IDs with DOBs more
than two days apart (more than three days apart for outpatient
deliveries) and less than 24 weeks apart. This step preserved
multifetal deliveries, but it removed deliveries that were unrea-
sonably close in time. To remove duplicate deliveries, we
combined linked deliveries from the same woman into one
delivery if the infants’ DOBs were less than three days apart (less
than four days for outpatient deliveries). For these deliveries, the
earliest DOB was selected as the infants’ DOB and the woman’s
delivery date.
Estimation of the Last Menstrual Period (LMP)
The date of the LMP was estimated because neither gestational
length nor the LMP is available in healthcare utilization data. It
was assigned to be 245 days before the infant’s DOB for
pregnancies that had maternal or infant ICD-9 codes indicative
of preterm delivery (644.0, 644.2, and 765.x) and to be 270 days
before the infant’s DOB for all other pregnancies [26].
Women’s Eligibility Criteria
MAX may contain an incomplete record of healthcare claims
for the linked women when they are not enrolled in Medicaid,
have supplemental private insurance, have restricted benefits, such
as pregnancy-related services or prescription drug benefits only, or
are enrolled in certain managed care plans [27]. Medicaid
beneficiaries can be enrolled in two major types of managed care
plans, capitated (i.e., risk-based) or fee-for-service primary care
case management (FFS PCCM), or they may not be enrolled in a
managed care plan (women not enrolled in these plans are referred
to as traditional beneficiaries) [28]. Encounter records, which take
the place of claims for services provided to patients enrolled in
capitated managed care plans, are incomplete in certain states
[29–30]. We implemented eligibility criteria based on these
Medicaid program provisions and arrangements to increase the
completeness of claim information among women included in the
cohort.
Women were excluded if any of the following four eligibility
criteria were not met, according to the PS file, in at least one
month during the eligibility period of interest: 1) Continuous
enrollment throughout the eligibility period, defined as at least
28 days of enrollment per calendar month. 2) No private
insurance. 3) No restricted benefits. 4) Appropriate enrollment
type (i.e., capitated managed care, FFS PCCM managed care, or
no managed care) depending on state (Table S2 in File S1). We
excluded women enrolled in capitated plans in states where they
had fewer claims compared to FFS PCCM or traditional
beneficiaries. Also, we excluded traditional beneficiaries in states
that had a high proportion of women with restricted benefits and
in which traditional beneficiaries had few claims; these women
likely had unidentified restricted benefits given the high proportion
of women with restricted benefits in these states. All pregnancies
were excluded in Michigan because the number of claims among
all enrollee types was implausibly low. We defined the primary
eligibility period (Figure 3) as the calendar month before the LMP
month until the calendar month after the delivery month or date
of death, whichever occurred first, to ensure follow-up throughout
pregnancy. We report the cohort size for the primary eligibility
period (i.e., the base cohort) and for shorter and longer eligibility
periods, which may also be of interest for certain research
questions.
Multiple MSIS_IDs and Infants’ Eligibility Criteria
MAX anomalies tables indicate that individuals may receive
more than one MSIS_ID within the same state [20]. Although it is
legitimate for multifetal pregnancies to have more than one infant
MSIS_ID, in at least some pregnancies with multiple infant
MSIS_IDs, infants may have been assigned a temporary MSIS_ID
at birth and later received a permanent MSIS_ID [20].
Figure 2. Hypothetical example of woman-infant linkage by state, Case Number, and delivery date range/date of birth. CA,
California.
doi:10.1371/journal.pone.0067405.g002
Figure 3. Schematic of the primary eligibility period.
doi:10.1371/journal.pone.0067405.g003
The Medicaid Analytic eXtract Pregnancy Cohort
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infant outcomes. Because we could not rule out multiple infant
MSIS_IDs per pregnancy as an indication of poor linkage quality,
we required more stringent eligibility criteria in those pregnancies:
if infant zip code was different from maternal zip code, then the
infant was excluded. Prior to applying infant eligibility criteria, zip
codes did not match in 5.5% of pregnancies linked to one infant
MSIS_ID, 25.7% of pregnancies linked to two MSIS_IDs, and
48.7% of pregnancies linked to three MSIS_IDs.
Because multiple infant MSIS_IDs that linked to the same
pregnancy may represent the same infant, we pooled eligibility
information from all infant MSIS_IDs associated with a pregnancy
and required that at least one infant MSIS_ID had either
Medicaid enrollment in the month after the birth month or a claim
in the month after birth. Pregnancies with neonatal death
remained eligible even if they did not meet the enrollment criteria.
Medication dispensings and Outcome Assessment
Pharmacy claim dates during pregnancy were used to identify
pregnant women who were dispensed a medication. Both inpatient




Overall, of the 10,058,005 identified inpatient deliveries, 55.6%
linked to at least one infant, and of the 3,402,268 outpatient (i.e.,
physician, clinic or outpatient hospital) delivery claims, 23.8%
linked to at least one infant. The delivery linkage percentages
varied greatly by state (Table 1). From the pool of 22,408,810 child
MSIS_ID-DOB combinations, 6.8% would not have met the
maternal eligibility criteria applied later because the child’s DOB
was within the first 9 months of 2000 or during December 2007
(i.e., data was not available during the maternal eligibility period),
and 24.4% linked to an inpatient delivery. Of the remaining
16,457,327 observations that did not link to an inpatient delivery,
3.9% linked to an outpatient delivery.
Post-linkage Cleaning
From the 6,401,483 linked deliveries, 293,911 (4.6%) were
removed in the post-linkage cleaning phase, resulting in the
identification of 6,107,572 unique pregnancies ending in live birth.
Of deliveries that were removed, 99.2% were combined with other
deliveries because they were duplicates and the rest appeared to be
incorrect linkages.
Eligibility Criteria
Of the eligibility criteria, the requirement of enrollment
throughout pregnancy had the greatest impact on the cohort size
(Figure 1). After all the eligibility criteria were implemented, the
base cohort consisted of 1,248,875 pregnancies from 1,072,352
women. The cohort size decreased to 633,553 pregnancies when
we required that women not be enrolled in capitated managed
care plans. The cohort size was sensitive to changes in the
maternal eligibility period (Figure 4), and it increased with
decreasing eligibility period length requirements. The size of the
base cohort was reduced when infant eligibility criteria were
implemented too; 1,173,280 (93.9%) pregnancies were available
when one month of infant eligibility was required (Figure 1).
Cohort Description
Figure 5 summarizes the number of pregnancies contributed to
the cohort from each state. The largest contribution was from
California with 257,148 pregnancies, and the smallest contribution
was from Washington, DC, with 533 pregnancies (Table S2 in File
S1); 50% of pregnancies were from six states (California, Illinois,
New York, Ohio, Tennessee, Wisconsin). The average maternal
age was 23.9 years, and 33% of women were Black and 18% were
Hispanic (Figure 6). Although women may belong to more than
one Medicaid eligibility group, only one group is recorded in
MAX; the largest Medicaid eligibility group in the cohort was
adults with dependent children. There are relatively few pregnan-
cies from 2000 because of the pre-delivery eligibility requirement.
Compared to pregnancies in the linked cohort before eligibility
criteria implementation, women in the base cohort were slightly
less likely to be white (40.8% vs. 47.4%), more likely to be eligible
due to child (15.7% vs 10.5%) or disability status (3.1% vs. 1.0%)
on the delivery date, and had a similar age distribution (Table S3
in File S1). In the infant outcomes cohort, 6% of pregnancies had
more than one infant MSIS_ID, and among pregnancies with only
one infant MSIS_ID, the percentage of pregnancies in which the
mother and infant did not share the same zip code was 4.9%
(Table S4 in File S1).
Overall, 91% of women had at least one pharmacy dispensing
during pregnancy (Table S2 in File S1). Oregon and South Dakota
had a relatively lower proportion of pregnant women with
pharmacy dispensings (41.6% and 65.3%). The percentage of
pregnancies affected by several outcomes is reported in Figure S1.
Discussion
We developed the methodology to utilize a promising and
previously untapped resource for studies of medication exposure
during pregnancy and a broad range of maternal and infant
outcomes. Healthcare utilization data offer a number of advan-
tages for studies of medications in pregnancy over pregnancy
registry and case-control studies including the availability of large,
population-based cohorts in which the study of rare outcomes and
important subgroups is feasible, the availability of exposed and
reference groups from the same population, prospectively collected
information on a range of prescription drugs, information on
many maternal and neonatal outcomes, and low study cost
compared to de novo data collection [5].
Several characteristics of the cohort have face validity. We
found that woman-infant pairs with zip codes that did not match
were uncommon in most states, which supports accurate linkage.
Zip codes may not match for reasons other than poor linkage;
infants may not live with their mothers, or maternal zip code may
not be current on the delivery date due to changes of residence.
Therefore, we did not require zip codes to match in pregnancies
with one infant MSIS_ID. Furthermore, the frequency of several
pregnancy outcomes was similar to expectations [31–32] and the
proportion of pregnancies with cesarean delivery tracked over time
with national trends [32–39], which further supports the data
validity. Although we excluded pregnant women who were not
linked to infants or did not meet eligibility criteria, these findings
suggest that the cohort may be representative of the broader
population.
There were several state-specific Medicaid program and data
quality factors that contributed to the large variation in the
number of pregnancies in the cohort from each state, including the
number of pregnant women covered by Medicaid, availability of
MAX for all study years, Medicaid benefit restriction and
eligibility policies for enrollees, the completeness of claims, quality
of Case Numbers, and reuse of Case Numbers within families. The
same Case Number is not necessarily shared by all family
members [22]. Consequently, fewer deliveries will be linked to
The Medicaid Analytic eXtract Pregnancy Cohort
PLOS ONE | www.plosone.org 5 June 2013 | Volume 8 | Issue 6 | e67405Table 1. The number of deliveries before linkage and the percentage of deliveries that linked to an infant, and the number of child
MSIS_ID and date of birth combinations before linkage and the percentage of combinations that linked to a delivery listed by
inpatient and outpatient linkage and by state; Medicaid Analytic eXtract, 2000–2007.


























AK 31553 83.4 7383 41.7 57433 45.9 30541 8.0
AL 335584 83.9 3177 54.0 357467 51.7 164090 1.0
AR 133629 21.7 111902 2.0 272989 10.6 243491 0.7
CA 905520 78.9 417779 38.3 3384571 21.1 2592491 5.4
CO 116192 79.3 12198 47.0 296181 31.1 202696 1.7
CT 20782 0 1970 0 164612 0 164612 0
DC 3927 80.4 915 26.4 51082 6.2 47841 0.3
DE 10149 93.2 23841 70.6 58891 16.1 49230 31.1
FL 543810 71.6 443337 7.1 1483965 26.3 1054754 1.6
GA 415916 35.9 100357 19.1 972752 15.4 812358 1.9
HI 27633 77.6 11758 65.1 74707 28.7 52894 12.9
IA 86326 73.0 21308 55.8 179092 35.2 115181 9.3
ID 61086 74.6 8050 46.8 92037 49.5 45823 5.8
IL 458715 72.3 156915 13.5 931766 35.0 600100 2.4
IN 222255 91.7 178780 18.0 433979 47.0 226903 10.1
KS 80230 90.9 12787 65.1 180418 40.4 105982 6.4
KY 175466 81.1 49526 40.8 336217 42.4 173547 9.0
LA 270481 88.2 138652 12.6 547583 43.6 208107 5.5
MA 81289 89.4 17975 33.4 319082 22.8 243566 1.3
MD 1470560 9.3 13016 10.8 321470 42.5 182008 0.6
ME 15566 93.0 3909 25.6 68627 21.1 53919 1.4
MI 177475 70.7 71736 26.6 626024 20.1 497896 2.9
MN 91875 93.8 70072 67.2 316557 27.2 214314 19.2
MO 253912 54.8 39871 31.2 402150 34.3 261520 3.8
MS 184337 90.2 93213 11.6 353758 47.3 138740 4.8
MT 27084 0 4093 0 52429 0 52429 0
NC 484133 17.3 44800 9.3 679462 12.3 594079 0.5
ND 16679 96.0 3334 36.2 33598 47.7 17335 4.4
NE 25261 79.7 8158 54.6 125239 16.1 104822 3.9
NH 22699 94.0 3519 46.6 55521 38.5 33832 3.4
NJ 89215 84.4 88993 53.4 521386 14.5 428403 9.8
NM 93901 85.4 28986 72.7 222010 36.1 129329 13.8
NV 31258 89.5 11527 75.4 180635 15.5 147048 5.0
NY 642194 52.1 107573 34.3 1396520 23.8 1056220 2.8
OH 252528 94.2 154680 17.1 725433 32.8 481332 2.6
OK 156994 87.9 37478 55.5 392679 35.2 243912 7.2
OR 98716 88.0 23427 60.2 235288 36.9 146705 7.8
PA 111772 93.0 17485 31.2 634621 16.3 529191 0.8
RI 46047 91.1 8280 31.4 63926 48.0 32622 4.8
SC 199463 16.1 116129 1.7 341982 9.4 309065 0.5
SD 30083 93.8 3170 50.1 59627 47.4 30916 4.0
TN 168714 80.0 71995 69.3 447117 30.2 309663 14.1
TX 831729 9.1 486918 1.0 2349734 3.2 2272382 0.1
UT 51991 95.7 9264 81.6 203126 24.5 152506 2.3
VA 151876 87.1 62204 58.6 391259 33.9 255155 12.2
The Medicaid Analytic eXtract Pregnancy Cohort
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to women and their infants. Woman-infant linkage is not necessary
for studies of healthcare utilization during pregnancy and maternal
outcomes [18,25], and delivery linkage less than 100% will
decrease the cohort size, perhaps unnecessarily for these studies.
However, falsely identified deliveries and incorrect delivery date
and LMP assignment are more likely when deliveries are not
linked to infants.
Investigators planning to work with the cohort should be aware
of a number of limitations inherent in the data and strategies to
address at least some of these issues. To begin with, we restricted
the cohort to live births only, because of the infant-linkage step, so
it cannot be used to study spontaneous abortion and stillbirths.
There is potential for selection bias if the exposure of interest is
associated with spontaneous abortion or stillbirth and there are
unmeasured common causes of these outcomes and the outcome
of interest [40–41]. However, many outcomes of interest (e.g.,
preeclampsia) are conditional on the fetus surviving at least twenty
weeks. As with many studies, this bias would mainly result in an
underestimation of fetal outcomes that are associated with
abortion. Moreover, the pre-linkage cohort could be used to study
stillbirth, although a validation study would be warranted.
The method we used to estimate the LMP accurately classified
gestational age within 2 weeks for nearly all term and 75% of
preterm pregnancies and was superior to other algorithms in one
healthcare utilization database [26]. Gestational age at delivery
could be obtained by linking MAX data with birth records, but
this is not possible at the national level. MAX data do not contain
direct personal identifiers such as names and addresses; however
social security numbers may be requested from CMS and could be
used for birth record linkage in states where social security
numbers are available in vital records. Also, multiparity was
estimated from the eligibility group and will be misclassified for
some women because only one eligibility group is available in
MAX data; e.g., women who are disabled and have previous
children may only be identified as being disabled instead of
multiparous. Because infants may have more than one MSIS_ID,
ICD-9 codes should be used to identify multiple gestations.
Furthermore, incorrect linkage, i.e., false woman-infant pairs,
could occur if the same Case Number was shared among different
families. To our knowledge, there is no CMS validation report
regarding the use of the Case Number within families. Incorrect
linkage would likely result in non-differential misclassification of
infant outcomes which would tend to bias associations towards the
null and is problematic for drug safety studies. Social security
numbers could be used to validate the linkage method in states
where they are available in birth records. It is advisable to conduct
sensitivity analyses restricted to a subcohort with potentially higher
linkage quality when using the cohort to study infant outcomes.
Table 1. Cont.


























VT 18386 91.9 2807 56.8 38560 43.9 20994 6.1
WA 117179 84.4 52704 63.9 427660 23.1 327281 8.8
WI 154097 94.0 33966 36.9 354202 40.9 174700 5.2
WV 40739 85.8 6237 47.5 149386 23.5 101601 2.1
WY 20999 93.9 4114 39.4 44000 45.0 23201 5.2
Total 10058005 55.6 3402268 23.8 22408810 24.4 16457327 3.9
doi:10.1371/journal.pone.0067405.t001
Figure 4. Cohort size by eligibility period; Medicaid Analytic
eXtract, 2000–2007. The number of pregnancies in the base cohort
(eligible from at least 1 month before the LMP month until the month
after the delivery month) is represented in red and the number of
pregnancies when additional or fewer months of eligibility are required
is represented in blue. The lengths of the eligibility periods decrease
when moving away from the vertical axis along the horizontal axis. –
indicates the number of months before the LMP and+indicates the
number of months after the LMP at which the eligibility period begins,
and all eligibility periods continue until the month after the delivery
month. LMP, last menstrual period; M, months.
doi:10.1371/journal.pone.0067405.g004
Figure 5. Number of pregnancies contributed to the base
cohort by state; Medicaid Analytic eXtract, 2000–2007.
doi:10.1371/journal.pone.0067405.g005
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statistical power when we implemented maternal eligibility
criteria. To ensure complete follow-up through pregnancy, 80%
of the originally identified pregnancies were removed. DeVoe
et al. reported that healthcare services were under-recorded in
Medicaid claims data from Oregon compared to electronic health
records [42]. To construct a cohort with a comprehensive picture
of healthcare services during pregnancy, we applied a number of
eligibility criteria that DeVoe et al. did not [43]. Although these
restrictions limit generalizability, they are critical for internal
validity. The variability in data quality by state forced us to restrict
to the states and enrollment types with acceptable quality and
completeness. The requirement of enrollment throughout preg-
nancy is coupled with a limitation: it effectively excluded women
who became eligible for Medicaid because of pregnancy.
Consequently, we selected a cohort of women who belong to
other Medicaid eligibility groups, i.e., those classified as children,
multiparae, and women with disabilities. Nevertheless, the
distribution of age and race was similar in the restricted and
unrestricted linked cohorts. The proportion of pregnancies
exposed to specific prescription drugs and the absolute risk of
outcomes may not generalize to the entire population of pregnant
women enrolled in Medicaid. The generalizability of measures of
association to all pregnant women enrolled in Medicaid and to
other populations will depend on differences in the distributions of
potential effect modifiers across the populations. Given the large
cohort size, measures of association should be stratified by
potential effect modifiers such as region, age, race, and parity;
stratum-specific results should generalize to non-Medicaid popu-
lations even if population averages do not. Moreover, studies
requiring shorter follow-up time will permit shorter eligibility
periods and therefore will have increased size and may have
greater generalizability.
Because date of death is under-recorded in MAX [44], it is
possible that we have unintentionally excluded women or infants
with apparent lack of eligibility whose date of death was missing.
Maternal and infant mortality is rare in the US [45–46]; we
anticipate few pregnancies were excluded due to under-recorded
date of death. Mortality could be studied if the data are linked to
the recently released 2008 MAX Date of Death Auxiliary File,
which contains more accurate and complete date of death
information [44].
Given the decentralized nature of Medicaid data and the sheer
number of enrollees, it is unlikely that all cohort members’ claims
will be captured in MAX even after applying strict eligibility
criteria. Sensitivity analyses should be performed that exclude
individuals who are least likely to have complete claim information
such as women enrolled in capitated managed care plans [29–30]
and from states that have a relatively low prevalence of various
exposures and outcomes.
Although medical record validation studies have been described
for Medicaid data among Medicaid and Medicare dually eligible
enrollees [47], the feasibility of obtaining medical records for
infant outcomes remains unknown. Medical records at birth may
not contain social security numbers or may not be released based
on social security numbers alone. MAX data contain hospital
identifiers but there is no centralized list of contact information for
these identifiers [27].
Some limitations of the MAX cohort are common to other
pregnancy cohorts assembled from healthcare utilization data,
such as the exclusion of pregnancies ending in miscarriage [9–
18,25] and the reliance on algorithms to estimate the date of the
Figure 6. The distribution of maternal characteristics in the base cohort; Medicaid Analytic eXtract, 2000–2007. A) Age, B) Race, C)
Medicaid Eligibility Group, and D) Delivery Year.
doi:10.1371/journal.pone.0067405.g006
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PLOS ONE | www.plosone.org 8 June 2013 | Volume 8 | Issue 6 | e67405LMP [11,14–16,18,25]. Furthermore, validity of mother-infant
linkage by subscriber or family number is not typically reported.
MAX contains a huge nationwide cohort of pregnant women
and prospectively collected data, which permits the study of rare
medication exposures and outcomes in an otherwise understudied
population. However, linkage of women to their infants is not
straightforward, enrollment time is limited for many pregnant
women in Medicaid because pregnancy qualifies some women for
Medicaid [23], restrictive eligibility criteria are necessary to reduce
incomplete claim information, gestational timing is not readily
available, and measurement error is unavoidable. The limitations
of MAX data may be overcome if investigators choose appropriate
study questions, employ careful methodology that favors validity
over statistical power, and perform sensitivity analyses to evaluate
the limitations of the data and the effect of various assumptions.
Ideally, MAX data should be linked to birth records to validate the
mother-infant linkage and to obtain additional birth information
such as gestational age and birth weight. The cohort size and
validity could be improved with modifications to MAX by state
Medicaid offices and CMS such as providing complete claim
information.
Cohort set-up is resource intensive, from requesting and
receiving the data from CMS to linkage and implementation of
eligibility criteria. However, once the cohort is assembled, it offers
an incredible opportunity to efficiently evaluate medication safety
during pregnancy as well as maternal characteristics, the impact of
Medicaid policy, and regional differences in healthcare utilization
during pregnancy.
Supporting Information
Figure S1 Cohort outcomes; Medicaid Analytic eXtract,
2000–2007. A) Percentage of pregnancies affected by preeclamp-
sia, severe preeclampsia, cesarean delivery, and preterm delivery
in the base cohort. B) Percentage of pregnancies with cesarean
delivery in the MAX cohort and in the United States according to
the National Vital Statistics System [32–39] by year for age groups
,20, 20–24, 25–29.
(TIF)
File S1 Supporting Information for MAX Pregnancy
Cohort. Table S1: Delivery-related procedure codes used to
identify inpatient and outpatient deliveries from the Medicaid
Analytic eXtract, 2000-2007. Table S2: Elements of the Case
Number used for linkage, enrollment type exclusions, number of
pregnancies, percentage of cohort, and percentage of pregnancies
with at least one prescription medication dispensed during
pregnancy by state; Medicaid Analytic eXtract, 2000–2007. Table
S3: Demographic characteristics on the delivery date among
women in the base cohort and women in the linked pre-eligibility
cohort; Medicaid Analytic eXtract, 2000–2007. Table S4. The
total number of pregnancies and the percentage of pregnancies
that have more than one infant MSIS_ID from the infant
outcomes cohort, and the number of pregnancies with one infant
MSIS_ID from the infant outcomes cohort and the percentage of
pregnancies in which woman-infant pairs did not share the same
zip code among pregnancies with one infant MSIS_ID from the
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